Journal of Isfahan Medical School

Journal of Isfahan Medical School

Up-regulation of SNHG5 Expression Level in Patients with Chronic Myeloid Leukemia Compared with Normal Individuals

Authors
Zahra Shahpouri-Arani 1
Mohamad Reza Hajari 2
Javad Mohammadi-Asl 3
Najmaldin Saki 4
1 MSc, Department of Biology, School of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
2 Assistant Professor, Department of Biology, School of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
3 Assistant Professor, Department of Genetics, School of Medicine, Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Associate Professor, Department of Laboratory Sciences, School of Paramedical Sciences, Jundishapur University of Medical Sciences, Ahvaz, Iran
10.48305/jims.2022.16290
Abstract
Background: Chronic myeloid leukemia is a type of myeloproliferative malignancy that is associated with translocation between chromosomes 9 and 22 and accounts for approximately 15% of all leukemia. SNHGs are a subset of long non-coding RNAs that are considered to host small nuclear RNAs. SNHG5 is a regulatory factor in gene expression in various cancers, including chronic myeloid leukemia. The aim of this study was to evaluate 
and compare the expression level of SNHG5 in the peripheral blood sample of patients with chronic myeloid leukemia compared to normal individuals and then to evaluate SNHG5 as a potential biomarker in these patients. 
Methods: This study was conducted with a case-control design. First, the accuracy of chronic myeloid leukemia was confirmed using karyotype, molecular and cellular methods. After RNA extraction from white blood cells and cDNA synthesis, gene expression was measured using Real Time PCR. Finally, the data were statistically analyzed.
Findings: Findings of this study showed that the expression level of SNHG5 in patients with chronic myeloid leukemia significantly increased compared to normal individuals (P < 0.001). Increased expression may indicate the potential role of this molecule in the development and progression of this cancer.
Conclusion: The present study demonstrates the effective role of SNHG5 in the progression of chronic myeloid leukemia and can be investigated as a biomarker and potential therapeutic target in future studies
Keywords
Biomarkers
Chronic myeloid leukemia
Case- control studies
Long non-coding RNA SNHG5
  1. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113(8): 1619-30.
  2. O’Brien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 2009; 7(9): 984-1023.
  3. Kaleem B, Shahab S, Ahmed N, Shamsi TS. Chronic myeloid leukemia--prognostic value of mutations. Asian Pac J Cancer Prev 2015; 16(17): 7415-23.
  4. Usmani SZ, Yunus SA, Jamal Y. Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era. Asian Pac J Cancer Prev 2009; 10(6): 1039-40.
  5. Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119(9): 1981-7.
  6. Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol 2013; 97: 183-97.
  7. Takahashi N, Miura M. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. Pharmacology 2011; 87(5-6): 241-8.
  8. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011; 43(6): 904-14. 
  9. Gao P, Wei GH. Genomic insight into the role of lncRNA in cancer susceptibility. Int J Mol Sci 2017; 18(6):
  10. Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia, dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010; 3: 47.
  11. Ma Z, Xue S, Zeng B, Qiu D. lncRNA SNHG5 is associated with poor prognosis of bladder cancer and promotes bladder cancer cell proliferation through targeting p27. Oncol Lett 2018; 15(2): 1924-30.
  12. Li J, Sun CK. Long noncoding RNA SNHG5 is up-regulated and serves as a potential prognostic biomarker in acute myeloid leukemia. Eur Rev Med Pharmacol Sci 2018; 22(11): 3342-47.
  13. He B, Bai Y, Kang W, Zhang X, Jiang X. LncRNA SNHG5 regulates imatinib resistance in chonic myeloid leukemia via acting as a CeRNA against MiR-205-5p. Am J Cancer Res 2017; 7(8): 1704-13.
  14. Gao B, Li S, Li G. Long noncoding RNA (lncRNA) small nucleolar RNA host gene 5 (SNHG5) regulates proliferation, differentiation, and apoptosis of K562 cells in chronic myeliod leukemia. Med Sci Monit 2019; 25: 6812-9.
  15. Redaelli A, Bell C, Casagrande J, Stephens J, Botteman M, Laskin B, et al. Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther 2004 ; 4(1): 85-96.
  16. Efficace F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M, et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 2021; 81(2): 123-35.
  17. Saglio G, Sharf G, Almeida A, Bogdanovic A, Bombaci F, Čugurović J, et al. Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient-physician perspective. Clin Lymphoma Myeloma Leuk 2018;
    18(6): 375-9.
  18. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22(39): 8031-41.
  19. Shi T, Gao G, Cao Y. Long noncoding RNAs as novel biomarkers have a promising future in cancer diagnostics. Dis Markers 2016; 2016: 9085195.
  20. Avazpour N, Hajjari M, Kazemi Nezhad SR, Tahmasebi Birgani M. SNHG1 long noncoding RNA is potentially up- regulated in  colorectal adenocarcinoma. Asian Pac J Cancer Prev 2020; 21(4): 897-901.
  21. Lee J, Ryu J, Lee C. Strong cis-acting expression quantitative trait loci for the genes encoding SNHG5 and PEX6. Medicine (Baltimore) 2016; 95(52):
Journal of Isfahan Medical School
Volume 40, Issue 659
3rd Week, April
March and April 2022
Pages 62-68

  • Receive Date 14 April 2022